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ABSTR ACT: Computed tomography (CT) has been used as the reference imaging technique for the initial staging of diffuse large B-cell lymphoma until 
recent days, when the introduction of positron emission tomography (PET)/CT imaging as a hybrid technique has become of routine use. However, the 
 performance of both examinations is still common. The aim of this work was to compare the findings between low-dose 2-deoxy-2-(18F)fluoro-d-glucose 
(18F-FDG) PET/CT and full-dose contrast-enhanced CT (ceCT) in 28 patients with localized diffuse large B-cell lymphoma according to PET/CT find-
ings, in order to avoid the performance of ceCT. For each technique, a comparison in the number of nodal and extranodal involved regions was performed. 
PET/CT showed more lesions than ceCT in both nodal (41 vs. 36) and extranodal localizations (16 vs. 15). Disease staging according to both techniques 
was concordant in 22 patients (79%) and discordant in 6 patients (21%), changing treatment management in 3 patients (11%). PET/CT determined a better 
staging and therapeutic approach, making the performance of an additional ceCT unnecessary.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common 
type of lymphoma, representing approximately 30% of all 
lymphomas and appearing in a localized stage in about 30% of 
the cases. It is a fast growing neoplasm, with high prolifera-
tive rate and favorable response to chemotherapy. Complete 
response after first-line treatment ranges about 70%–80%, 
with a five-year survival rate over 60%.1
Once the diagnosis is established, it is of paramount 
importance to define the extension of the disease in order 
to evaluate the individual prognostic and the best thera-
peutic approach. Computed tomography (CT) has been the 
most commonly used imaging technique until recent days;2 
its diagnostic criteria depend on size, shape, and contrast 
enhancement of lesions. On the other hand, fundamentals 
of positron emission tomography (PET) are based on the use 
of certain molecules labeled with radioactive isotopes (posi-
tron emitters), which allow obtaining functional images. The 
most commonly used radiopharmaceutical is 2-deoxy-2-(18F)
fluoro-d-glucose (18F-FDG), a glucose analog that is captured 
by cells with high metabolic needs.3 The introduction of the 
hybrid technique PET/CT provides metabolic and anatomic 
information, solving the main limitations of both techniques 
separately, improves anatomic resolution of PET, and allows 
the detection of increased metabolic activity in lymph nodes 
and organs without CT abnormalities.
However, in some centers, a thoracic and abdominal 
contrast-enhanced CT (ceCT) scan is still of routine use 
for staging of lymphomas, as it is a highly available exam-
ination and in many situations is used as the initial test in 
patients with constitutional symptoms, while PET/CT is a 
less accessible technique in which the use of iodinated con-
trast is controverter. The aim of our work was to compare 
noncontrast-enhanced PET/CT with ceCT in patients with 
localized DLBCL according to PET/CT findings, with the 
purpose of avoiding the performance of a ceCT.
Patients and Methods
Patients. This is a retrospective study of 28 patients 
(16  male) with a median age of 59 years, diagnosed of 
DLBCL between 2007 and 2011, in a localized stage accord-
ing to PET/CT findings. The characteristics of the patients are 
detailed in Table 1. In agreement with the Cotswold modifica-
tion of Ann Arbor classification, localized disease is defined 
as involvement of nodal territories in the same side of the 
diaphragm, or as a disease that is primarily originated in an 
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extralymphatic organ, with or without regional nodal involve-
ment (stages I–II).4 Evaluation of our patients included an 
anamnesis, physical examination, hemogram, biochemistry, 
hepatic and renal parameters, lactate dehydrogenase (LDH), 
β2-microglobulin and viral serologies, chest X-ray, and bone 
marrow biopsy. All of them underwent a PET/CT without 
iodinated contrast (low dose) and a ceCT (high dose). Time 
interval between both tests was no longer than two weeks; dur-
ing this time frame, none of the patients received any treat-
ment. Patients with neck involvement on PET/CT who did 
not have a cervical ceCT of this area were excluded from the 
study. All the patients were subsequently controlled, either by 
PET/CT or clinically.
Examination protocol.
PET/CT. All data were acquired in a hybrid tomograph 
Discovery ST (GE Healthcare), 60–120 minutes after the 
injection of 3.7 MBq/kg (0.1 mCi/kg) of 18F-FDG. Patients 
fasted for at least six hours and were abundantly hydrated. 
In all of them, glucose level was tested immediately before 
radiotracer injection, to make sure that it was lower than 
7.78 mmol/L.
Whole-body acquisition protocol included a CT scan 
(140 kV and 80 mA) and a PET (three minutes per field of 
view) in a two-dimensional mode for patients scanned before 
2009 and in a three-dimensional mode afterward. CT images 
were used for attenuation correction and anatomical localiza-
tion of PET findings.
Contrast-enhanced CT. Thoracoabdominal studies were 
acquired in two multidetector CT units, one BrightSpeed and 
one LightSpeed VCT (GE Healthcare) of 16 and 64 detec-
tors, respectively (140  kV and dose-modulated current with 
a maximum of 300 mA), after intravenous administration of 
100–150 mL (according to each patient’s weight) of a nonionic 
iodinated contrast agent at 4–4.5 mL/second.
Data analysis. Images were independently evaluated by 
experienced specialists in nuclear medicine (PET/CT) and 
radiology (ceCT), identifying the number of nodal and extra-
nodal involved localizations.
In PET/CT technique, positive lesions were considered 
as areas of focal or diffuse FDG uptake (higher than the 
background) in nonphysiologic localizations (including lymph 
nodes of less than 1 cm and normal size organs). The criteria 
to consider positive lesions on ceCT included lymph nodes 
over than 1 cm in the shorter axis, increased organ size, and/
or abnormal contrast uptake.
Results
In the evaluation of nodal and extranodal localizations, PET/
CT showed the involvement of 41 and 16 territories, and 
CT showed the involvement of 36 and 15 territories, respec-
tively. The distribution of affected territories according to each 
technique is listed in Table 2. In view of PET/CT findings, 
16 patients were considered as stage I (57%) and 12 as stage II 
(43%), while CT findings classified them as stage I in 13 cases 
(46.4%), stage II in 13 other patients (46.4%), and advanced 
disease (stages III and IV) in 2 of them (7.1%). Comparing 
both imaging techniques, 22 cases were concordant (79%) 
and 6 were discordant (21%); the latter are further detailed in 
Table 3. In three of these discordant patients, a change of stage 
also implied a change in the therapeutic approach (diminish-
ing the number of chemotherapy cycles). All patients were 
treated with standard chemotherapy.
Discussion
For a long time, ceCT has been the most widely used imaging 
technique for the study of lymphomas; however, in the past 
few  years, PET/CT has proved superior in initial staging, 
relapse, and response assessment of FDG-avid lymphomas, 
as pointed in the last Lugano classification.5–10 Nevertheless, 
PET/CT is usually performed with a low-dose CT and without 
iodinated contrast, mainly used for anatomic localization and 
attenuation correction. In this setting, the hybrid examina-
tion is often performed as complementary to ceCT. Could a 
low-dose PET/CT be enough for disease staging, consequently 
decreasing radiation dose to the patient? Different groups have 
Table 2. distribution of nodal and extranodal involved territories 
according to Pet/Ct and ceCt.
NODAL PET/CT ceCT EXTRANODAL PET/CT ceCT
Cervical 5 4 Bone 1 1
axillary 1 0 orbita 1 1
Mediastinal 7 6 Parotid gland 1 1
Pulmonary hilum 1 0 thyroid 1 1
abdominal 10 12 Breast 1 0
retroperitoneal 10 6 lung 1 1
Pelvic 6 6 liver 0 1
spleen 0 1 Peritoneum 1 1
Waldeyer’s ring 1 1 gastrointesti-
nal tract
9 8
41 36 16 15
Table 1. Patient characteristics.










Note: aStage according to PET/CT findings and in agreement with the 
Cotswold classification.
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Table 3. Discordant findings between ceCT and low-dose PET/CT.
CASES ceCT PATHOLOGIC FINDINGS ceCT 
STAGE




1 right cervical lymph nodes i Bilateral cervical and 
pulmonary hila lymph 
nodes
– ii indeterminate lymph 
nodes in the pulmonary 
hila at ceCt
2 gastric wall thickening, perigastric 
and hepatoduodenal lymph nodes 
ii gastric wall thickening Perigastric and hepato-
duodenal lymph nodes
i –
3 Post-surgical changes (intestinal 
lymphoma) and splenomegaly
ii Post-surgical changes 
(intestinal lymphoma)
splenomegaly i reactive splenomegaly 
(hiV)
4 Mass with pharyngeal and parotid 
gland involvement. supraclavicular 
and mediastinal lymph nodes 
ii Mass with pharyngeal 






5 left cervical and mesenteric lymph 
nodes





6 Bulky mediastinal mass with superior 
caval vein thrombosis, peripheric 
lymph nodes and hepatic lesion
iV Bulky mediastinal 
mass and peripheric 
lymph nodes
hepatic lesion ii hepatic lesion described 
as hemangioma in 
follow-up ceCt
Abbreviation: HIV, human immunodeficiency virus.
already studied this topic,11–14 comparing sensitivity and spec-
ificity of a low-dose, noncontrast-enhanced PET/CT with a 
high-dose ceCT (coregistered with the PET acquisition or 
independently performed). These studies did not find any sig-
nificant difference among two CT modalities regarding nodal 
or extranodal, even a low-dose PET/CT could detect more 
lesions.12,14–17 Another point of discussion and of interest for 
our group is finding out if a low-dose noncontrast-enhanced 
PET/CT for initial staging of patients with DLBCL local-
ized disease (I–II) avoided high-dose ceCT. In this sense, 
Rodríguez-Vigil et al11 published data comparing the results 
obtained with and without iodinated contrast in a PET/CT 
scanner and avoiding high-dose ceCT. They did not find any 
significant differences in the number of nodal and extranodal 
involved regions. However, Schaefer et al12 included patients 
with both Hodgkin’s disease and non-Hodgkin lymphomas in 
different stages, 30 of them in stage IV.
In our study, the unique selection of patients with local-
ized disease was intended to limit the possibility of differences 
between both imaging techniques, studying patients with low 
tumor volume. In our opinion, discordant results increased 
including patients with advanced stages, as occurred in the 
previously cited works.11,12 In the current study, low-dose 
PET/CT detected more lesions than ceCT, nodal (41 vs. 36) 
and extranodal (16 vs. 15), similar to those mentioned in the lit-
erature for aggressive lymphomas.12,15–17 Differences observed 
in nodal involvement could be explained by the capacity of 
PET/CT to prove that involvement of infra lymph nodes lesser 
than 1 cm are not considered pathologic on the CT.18 Regard-
ing extranodal locations, differences could be explained due 
to the decision to include only localized stages, some of them 
with primary extranodal involvement (10 cases, 36%).
Analyzing particularly Ann Arbor stage of the disease, 
six patients (21%) were discordant between the two imaging 
procedures (Fig. 1). In one patient, PET/CT upstaged the 
disease and downstaged in five of them, changing the thera-
peutic management in three of them (11% of all patients), lead-
ing to a reduction of cycles of chemotherapy. In the study by 
Schaefer et al,12 PET/CT changed the therapeutic approach 
in up to 16% of patients.
It is important to note some limitations of our study. For 
instance, we are aware of the retrospective nature of the study 
and the small number of patients. However, the population 
included is histologically homogeneous, and both imaging 
procedures were performed following proper standards and at 
appropriate time intervals.
Conclusion
Low-dose, noncontrast-enhanced PET/CT is a very good 
imaging technique for initial staging of DLBCL. Consider-
ing localized lymphomas, the current results demonstrate a 
better performance of PET/CT when compared with ceCT 
in detecting both nodal and extranodal lesions, précising the 
disease extension and allowing a better therapeutic approach. 
In this group of patients, an additional high-dose ceCT could 
be avoided.
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Figure 1. sixty-two year-old woman diagnosed with dlBCl. ceCt showed pharyngeal involvement with extension to the right parotid gland, as well as 
supraclavicular and mediastinal lymph nodes of up to 11 mm (A, red arrow). Pet/Ct proved high hypermetabolism in the pharyngeal lesion (B), even 
if supraclavicular and mediastinal lymph nodes did not show increased uptake of 18F-Fdg (C, blue arrow). due to the absence of pathologic metabolic 
activity, these lymph nodes were not considered as disease involvement, classifying the patient as stage I. According to ceCT findings, she would have been 
classified as stage II.
